More gains ahead for Undervalued Tetra Bio Pharma!

Consolidation is happening presently, SP has a median value of .86$ per share, key support @ .76, support @ .79, Resistance @ .86$; days high @ .90 ps. Average guidance is bullish with .86$ per share daily target. Renewed gains for the short term evident from short term higher highs and highers lows with key supports. Volume increasing. New short term highs indicate resistance is fragile to .94$ ps with increasing volume. Share price target by Oct 17th/18 range bound 1.05$ - 2.05$ per share. Lower range is indicative of projected figures (52 - point); Upper range is indicative of announcements (Not including stage 3 trial data). Unable to determine effects of Stage 3 clinical data on analysis for the long term. Analyst price target 2.30$ per share. Writers Price target: new 52 weeks highs prior to year end. In short, the value of Tetra bio-pharma at present does not reflect the valuation of the company with successful stage 3 trials as it will have a substantial effect on the share price. Successful preliminary data on stage 3 trials for PPP001 will guarantee success for PPP002 and PPP005 as the same chemical makeup is used. The SP for Tetra Bio Pharma with preliminary data on Stage 3 trials will likely add $300 million on top of the current market cap of 125$ million. Subsequently, the company will likely reach a half billion$ evaluation on those results prior to November, 2018.

Genacol partnership will begin to add value for Tetra Bio Pharma shareholders in the near term. - Projected 0.00 EPS Q1, 2019; 0.02 Q2 2019; .05$ EPS Q3 2019.
Upcoming Catalyst: North Bud IPO; Stage 3 preliminary Data; Additional Analyst coverage; Gov't FDA announcements; Additions to the board.
Fair Price for Tetra Bio-Pharma currently stands @ 1.24$ per share.